Physician profile
Donna E Kaiser
NPI 1972886950
$1,715.45
in general payments reported to CMS, 2019-2025
21 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $103 · 2023: $287 · 2024: $920 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $383.56 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $240.20 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $175.53 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $116.44 | 2023-2024 | |
| Glaxosmithkline, LLC. | $106.72 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $105.32 | 2021-2025 | Otezla, Repatha, Otezla |
| Abbott Laboratories | $90.57 | 2023-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $70.92 | 2021-2023 | |
| Inspire Medical Systems, INC. | $52.31 | 2023-2024 | Inspire |
| Pfizer INC. | $48.46 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.04 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $43.46 | 2022-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $40.59 | 2021-2024 | |
| Corcept Therapeutics | $36.97 | 2024 | Korlym |
| Merck Sharp & Dohme LLC | $34.18 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.90 | 2023-2024 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $27.47 | 2021-2022 | |
| Exact Sciences Corporation | $21.82 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.77 | 2022 | |
| Currax Pharmaceuticals LLC | $15.30 | 2025 | Contrave, Onzetra Xsail |
| Biohaven Pharmaceuticals, INC. | $13.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Kaiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.